期刊
CANCERS
卷 14, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/cancers14112795
关键词
super-resolutionmicroscopy; breast cancer; trastuzumab; therapy response; HER2; clustering
类别
资金
- Excellence Award from City of Hope, Circle 1500 seed grant, Conrad N. Hilton Foundation Pilot Award, Beckman Research Institute of the City of Hope [CA189283]
- Breast Cancer Research Foundation
- Harold E. Lee Chair for Cancer Research
- National Cancer Institute of the National Institutes of Health [P30CA033572]
This study used quantitative single molecule localization microscopy to assess the molecular features of HER2 in a therapy-responsive setting and found that the nano-organization of HER2 could potentially serve as a signature of therapy-responsive disease.
Trastuzumab, the prototype HER2-directed therapy, has markedly improved survival for women with HER2-positive breast cancers. However, only 40-60% of women with HER2-positive breast cancers achieve a complete pathological response to chemotherapy combined with HER2-directed therapy. The current diagnostic assays have poor positive-predictive accuracy in identifying therapy-responsive breast cancers. Here, we deployed quantitative single molecule localization microscopy to assess the molecular features of HER2 in a therapy-responsive setting. Using fluorescently labeled trastuzumab as a probe, we first compared the molecular features of HER2 in trastuzumab-sensitive (BT-474 and SK-BR-3) and trastuzumab-resistant (BT-474(R) and JIMT-1) cultured cell lines. Trastuzumab-sensitive cells had significantly higher detected HER2 densities and clustering. We then evaluated HER2 in pre-treatment core biopsies from women with breast cancer undergoing neoadjuvant therapy. A complete pathological response was associated with a high detected HER2 density and significant HER2 clustering. These results established the nano-organization of HER2 as a potential signature of therapy-responsive disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据